Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis
- PMID:39231480
- PMCID: PMC11464399
- DOI: 10.1038/s41586-024-07993-x
Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis
Abstract
Hyperlipidaemia is a major risk factor of atherosclerotic cardiovascular disease (ASCVD). Risk of cardiovascular events depends on cumulative lifetime exposure to low-density lipoprotein cholesterol (LDL-C) and, independently, on the time course of exposure to LDL-C, with early exposure being associated with a higher risk1. Furthermore, LDL-C fluctuations are associated with ASCVD outcomes2-4. However, the precise mechanisms behind this increased ASCVD risk are not understood. Here we find that early intermittent feeding of mice on a high-cholesterol Western-type diet (WD) accelerates atherosclerosis compared with late continuous exposure to the WD, despite similar cumulative circulating LDL-C levels. We find that early intermittent hyperlipidaemia alters the number and homeostatic phenotype of resident-like arterial macrophages. Macrophage genes with altered expression are enriched for genes linked to human ASCVD in genome-wide association studies. We show that LYVE1+ resident macrophages are atheroprotective, and identify biological pathways related to actin filament organization, of which alteration accelerates atherosclerosis. Using the Young Finns Study, we show that exposure to cholesterol early in life is significantly associated with the incidence and size of carotid atherosclerotic plaques in mid-adulthood. In summary, our results identify early intermittent exposure to cholesterol as a strong determinant of accelerated atherosclerosis, highlighting the importance of optimal control of hyperlipidaemia early in life, and providing insights into the underlying biological mechanisms. This knowledge will be essential to designing effective therapeutic strategies to combat ASCVD.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures














Comment in
- Lower your cholesterol early, and stick with it!Swirski FK, Binder CJ.Swirski FK, et al.Nat Rev Cardiol. 2025 Feb;22(2):69-70. doi: 10.1038/s41569-024-01095-x.Nat Rev Cardiol. 2025.PMID:39424909No abstract available.
Similar articles
- Exploring the impact of housing insecurity on the health and well-being of children and young people: a systematic review.Hock E, Blank L, Fairbrother H, Clowes M, Cuevas DC, Booth A, Goyder E.Hock E, et al.Public Health Res (Southampt). 2023 Dec;11(13):1-71. doi: 10.3310/TWWL4501.Public Health Res (Southampt). 2023.PMID:39789922
- Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Añino Alba A, Gómez Álvarez P, Fernandez-Esteban I, Saiz LC, Martin-Carrillo P, Pinar López Ó.Izquierdo-Palomares JM, et al.Cochrane Database Syst Rev. 2016 Nov 26;11(11):CD009462. doi: 10.1002/14651858.CD009462.pub2.Cochrane Database Syst Rev. 2016.PMID:27888640Free PMC article.Review.
- Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice.Yamamoto H, Yamanashi Y, Takada T, Mu S, Tanaka Y, Komine T, Suzuki H.Yamamoto H, et al.Mol Pharmacol. 2019 Jul;96(1):47-55. doi: 10.1124/mol.119.115840. Epub 2019 May 7.Mol Pharmacol. 2019.PMID:31064810
- ApoE Receptor-2 R952Q Variant in Macrophages Elevates Soluble LRP1 to Potentiate Hyperlipidemia and Accelerate Atherosclerosis in Mice.Turkson V, Haller A, Jaeschke A, Hui DY.Turkson V, et al.Arterioscler Thromb Vasc Biol. 2025 Jan;45(1):37-48. doi: 10.1161/ATVBAHA.124.321748. Epub 2024 Nov 7.Arterioscler Thromb Vasc Biol. 2025.PMID:39508104
- Intratympanic corticosteroids for Ménière's disease.Webster KE, Lee A, Galbraith K, Harrington-Benton NA, Judd O, Kaski D, Maarsingh OR, MacKeith S, Ray J, Van Vugt VA, Westerberg B, Burton MJ.Webster KE, et al.Cochrane Database Syst Rev. 2023 Feb 27;2(2):CD015245. doi: 10.1002/14651858.CD015245.pub2.Cochrane Database Syst Rev. 2023.PMID:36847608Free PMC article.Review.
Cited by
- Effects of diet on atherosclerotic plaque development.Greenhill C.Greenhill C.Nat Rev Endocrinol. 2024 Nov;20(11):631. doi: 10.1038/s41574-024-01044-1.Nat Rev Endocrinol. 2024.PMID:39300318No abstract available.
- A mechanistic review of the pharmacological aspects of Kaempferide as a natural compound.Song B, Niu W, Zhang S, Hao M, Li Y, Chen Q, Li S, Tong C.Song B, et al.Heliyon. 2024 Sep 24;10(19):e38243. doi: 10.1016/j.heliyon.2024.e38243. eCollection 2024 Oct 15.Heliyon. 2024.PMID:39397988Free PMC article.Review.
- Lower your cholesterol early, and stick with it!Swirski FK, Binder CJ.Swirski FK, et al.Nat Rev Cardiol. 2025 Feb;22(2):69-70. doi: 10.1038/s41569-024-01095-x.Nat Rev Cardiol. 2025.PMID:39424909No abstract available.
- Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control.Kral M, Döring Y, Weber C.Kral M, et al.Signal Transduct Target Ther. 2024 Nov 7;9(1):313. doi: 10.1038/s41392-024-02032-7.Signal Transduct Target Ther. 2024.PMID:39511160Free PMC article.No abstract available.
References
- Domanski, M. J. et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J. Am. Coll. Cardiol.76, 1507–1516 (2020). - PubMed
- Kim, M. K. et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation138, 2627–2637 (2018). - PubMed
- Bangalore, S. et al. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J. Am. Coll. Cardiol.65, 1539–1548 (2015). - PubMed
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous